Quantification of proteins and protein interactions with hitherto unseen sensitivity and specificity
Start-up Actome GmbH closes seed financing round
Actome GmbH, a life‐science start‐up company from the University of Freiburg and Hahn‐Schickard,
Germany has closed a seed investment agreement with b.value AG, Düsseldorf, Germany and further
investors. The seed investment will be used to establish the operative business and to bring Actome’s
first commercial products to the market. The first in class products will support life science researchers
by enabling the quantification of proteins and protein interactions in biological samples with hitherto
unseen sensitivity and specificity.
Actome GmbH
The unique performance of Actome’s products is based on the patented "Emulsion Coupling" technology
that detects single protein molecules and protein interaction complexes by translating protein status into
DNA‐barcodes. These barcodes are then detected by the method of digital PCR and decoded by a
proprietary software developed by Actome. “Our technology expands the capabilities of digital PCR from
nucleic acids to proteins. The application of our technology in the fields of proteomics, molecular pathway
research and biomarker discovery will help to increase our knowledge about molecular biological processes
and will transform medical diagnostics in an unprecedented way.” says Csaba Jeney, co‐founder, CEO, and
inventor of the technology.
Proteins control and direct biological processes through their interactions, the so‐called interactome, by
which they determine our health and wellbeing. Tools to study the interactome enable the understanding
of cellular processes and open up an enormous potential for research, diagnostics and therapies. Tackling
these challenges, Actome's innovative technology is a breakthrough that will revolutionize research and
biomedicine. The managing director of b.value AG, Peter Kallien, is excited about these opportunities:
“This is why Actome fascinated us from the first moment on. We have been impressed how the team
developed an extraordinary precise technology with huge benefits for proteomics research, which will allow
to define better diagnostic biomarkers and therapies.”
In addition to the investment, b.value AG will actively support Actome’s business development in the
future to increase outreach and accelerate growth. Further continued support by the University of
Freiburg, Hahn‐Schickard, BadenCampus, Life‐science Accelerator Baden‐Württemberg, bwcon and
Science4life is gratefully acknowledged by Actome.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
